| Nov 20 |
Unpacking the Latest Options Trading Trends in AbbVie
|
| Nov 19 |
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
|
| Nov 19 |
Where Will AbbVie Be in 5 Years?
|
| Nov 19 |
RVPH: Year-End OLE Update
|
| Nov 19 |
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
|
| Nov 18 |
AbbVie snaps eight straight sessions of losses
|
| Nov 18 |
Aldeyra announces FDA acceptance of resubmitted reproxalap application
|
| Nov 18 |
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
|
| Nov 18 |
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
|
| Nov 18 |
AbbVie’s Elahere wins European approval for certain ovarian cancers
|
